GSK reports £5.7 billion net profit in 2025, up from £2.6 billion in 2024, fueled by strong sales of HIV, respiratory, and cancer drugs, recovering from costly US Zantac lawsuits
British pharmaceutical company GSK has reported a sharp rise in net profit for 2025, driven by robust sales of HIV, respiratory, and cancer medicines and a recovery from costly US Zantac lawsuits.
Profit after tax climbed to £5.7 billion ($7.8 billion), up from £2.6 billion in 2024, while revenue increased four per cent to £32.7 billion, the company said in a statement.
“GSK delivered another strong performance in 2025, driven mainly by Speciality Medicines,” said CEO Luke Miels, who took over from Emma Walmsley at the start of the year.
“We expect this positive momentum to continue in 2026.”
The company forecasts low double-digit revenue growth in its speciality medicines division this year but expects revenue from vaccines and general medicines to decline.
GSK’s 2025 earnings benefitted from settling US lawsuits over its heartburn drug Zantac, paying $2.3 billion without admitting liability.
The US accounted for over half of the company’s total revenues.
Shares in GSK opened roughly two per cent higher on the London Stock Exchange, reflecting confidence in the company’s performance and outlook.
